ABSTRACT
Trp6]LH-RH or related analogs that can be injected once a month should make the treatment of patients with prostate carcinoma and other neoplasms or disorders more convenient and efficacious.
A marked inhibition of pituitary and gonadal function that occurs after chronic administration of the D-Trp6 analog of luteinizing hormone-releasing hormone (LH-RH) and other LH-RH agonists (1) (2) (3) (4) (5) (6) (7) (8) (9) leads to a chemical castration and makes possible an additional approach for the treatment of sex hormone-dependent tumors (10, 11) . In previous studies we have shown that chronic administration of [D-Trp6]LH-RH suppressed prostate tumor growth in two different rat models (12, 13) . In rats with prostate tumors treated with [D- Trp6]LH-RH, tumor weights and volumes, the weights of accessory sex organs, and serum levels of testosterone and prolactin were greatly reduced as compared to controls (12, 13) . These studies demonstrated the potential clinical efficacy of last from a few minutes to several hours. These modes of administration, with fluctuating blood levels of the peptide, may not achieve the optimal pharmacological effects. Consequently, higher-dosage regimens and greater frequency of administration may be needed to obtain these effects. A peptide administered by a controlled delivery system that would lead to a constant release over a prolonged period of time could provide a continuous biological effect. Recently, a polymer of poly(DL-lactide-co-glycolide) (PLG) has been used to formulate microcapsules with steroids for long-acting contraceptive delivery systems (22) (23) (24) (26) .
Serum levels of prolactin, growth hormone, and testosterone were measured by radioimmunoassays (RIAs) as previously described (12, 13) . The levels of [D-Trp6]LH-RH were measured by an RIA developed in this laboratory, using an antiserum generated against [D-Trp6]LH-RH (27) .
[ compared to controls. Testes weights in the group given microcapsules and injected s.c. were reduced by 60% (P = 0.01) and 42% (P = 0.01), respectively, but neither group showed significant changes in body weight or the weights of the anterior pituitary gland or adrenal gland (Table 1) .
In a second experiment, using the same design as in the first, [D-Trp6]LH-RH was given s.c. at a dose of 25 ,ug b.i.d., double that of the microcapsule formulation. Tumor weights in the microcapsule-injected group were decreased by 82% (P = 0.01); a reduction similar to that seen in the first experiment (Table 1) . Although tumor weights in the group injected s.c. were reduced by 54% as compared to controls (P = 0.05), doubling the s.c. dose of [D-Trp6]LH-RH was no more effective in decreasing tumor weight than the microcapsules. Again, on a percentage change basis both treatments reduced tumor volume. Ventral prostate weights were decreased in the group treated with microcapsules by 87% (P = 0.01) and in the s.c. injected group by 84% (P = 0.01), while the weights of the testes were reduced by 59% (P = 0.01) in the former group as compared to 52% (P = 0.01) in the latter. Body weights, anterior pituitary, and adrenal weights were not altered by this treatment as compared to control rats. blood levels in normal and experimental rats bearing prostate tumors is reported elsewhere (27) .
DISCUSSION
The androgen dependency of the Dunning prostate adenocarcinoma R3327H is well documented (29) (30) (31) 
